Table 1.
Baseline characteristic of patients with colorectal cancer divided by survival and non-survival patients, including biochemical and clinicopathological variables.
| Variables | Survival | Non-survival | p value |
|---|---|---|---|
| N=262 | N=196 | ||
| Age, years | 67.1 (11.9) | 71.8 (11.4) | <0.001*** |
| Sex, (Males vs Females): | 0.098 | ||
| Males, | 138 (54.5%) | 123 (62.8%) | |
| Females, | 115 (45.5%) | 73 (37.2%) | |
| Weight, kg | 73.9 (12.9) | 72.2 (14.5) | 0.256 |
| Body-mass index, kg/m² | 27.6 (4.39) | 27.5 (6.47) | 0.855 |
| Fasting glucose plasma, mg/dL | 110 (38.5) | 119 (58.8) | 0.055 |
| HbA1c, % | 15.7 (27.9) | 6.61 (1.45) | 0.356 |
| Total cholesterol, mg/dL | 178 (45.9) | 169 (47.9) | 0.309 |
| Triglycerides, mg/dL | 133 (76.1) | 134 (58.7) | 0.955 |
| HDL cholesterol, mg/dL | 46.4 (12.9) | 41.1 (16.0) | 0.304 |
| LDL cholesterol, mg/dL | 107 (45.8) | 105 (45.7) | 0.867 |
| Type 2 Diabetes Mellitus, %: | 1.000 | ||
| No | 187 (73.9%) | 144 (73.5%) | |
| Yes | 66 (26.1%) | 52 (26.5%) | |
| Alcohol consumption, %: | 0.300 | ||
| No | 142 (68.9%) | 114 (74.5%) | |
| Yes | 64 (31.1%) | 39 (25.5%) | |
| Smoking, %: | 0.499 | ||
| No | 198 (85.0%) | 136 (81.9%) | |
| Yes | 35 (15.0%) | 30 (18.1%) | |
| Familial history of colorectal cancer | 0.096 | ||
| No | 126 (49.8%) | 114 (58.2%) | |
| Yes | 127 (50.2%) | 82 (41.8%) | |
| Tumor site: | 0.235 | ||
| Rectum | 32 (12.6%) | 17 (8.67%) | |
| Colon | 221 (87.4%) | 179 (91.3%) | |
| Tumor grade histology: | 0.060 | ||
| G1 | 93 (42.5%) | 44 (30.8%) | |
| G2 | 101 (46.1%) | 71 (49.7%) | |
| G3 | 21 (9.59%) | 23 (16.1%) | |
| Tumor stage, TNM | <0.001*** | ||
| I | 8 (4.42%) | 4 (2.61%) | |
| II | 83 (45.9%) | 35 (22.9%) | |
| III | 81 (44.8%) | 43 (28.1%) | |
| IV | 9 (4.97%) | 71 (46.4%) | |
| Histology grade | 0.005** | ||
| Low grade | 164 (80.0%) | 89 (65.9%) | |
| High grade | 41 (20.0%) | 46 (34.1%) | |
| Tumor size width, cm | 4.54 (1.78) | 4.47 (2.01) | 0.807 |
| Tumor size large, cm | 3.53 (1.66) | 3.30 (1.66) | 0.387 |
| Metastasis: | <0.001*** | ||
| No | 201 (90.5%) | 81 (48.8%) | |
| Yes | 21 (9.46%) | 85 (51.2%) | |
| Chemotherapy: | 0.698 | ||
| No | 139 (55.2%) | 102 (52.8%) | |
| Yes | 113 (44.8%) | 91 (47.2%) | |
| Radiotherapy: | 0.277 | ||
| No | 217 (94.3%) | 140 (90.9%) | |
| Yes | 13 (5.65%) | 14 (9.09%) | |
| Disease recurrence: | <0.001*** | ||
| No | 165 (90.7%) | 73 (69.5%) | |
| Yes | 17 (9.34%) | 32 (30.5%) | |
| KRAS mutation: | 0.062 | ||
| No | 22 (64.7%) | 32 (43.2%) | |
| Yes | 12 (35.3%) | 42 (56.8%) |
Data are represented as mean (SD) or n (%). Groups were divided according to survival outcomes after 5-years of follow-up. Asterisk indicates significant difference between groups according to the Mann Whitney test and Chi squared test was used for variables expressed as percentage (***p<0.001, **p<0.01). Histologic Type groups: G1.-Polypoid, pedunculated, Exophytic, Ulcerated or Ulcerated-central, Coliform and Vegetative, G2.-Necrotic, Ulcerated, and Ulcerated-necrotic, G3.-Mucinous, and G4.-Stenotic and Stenotic-ulcerated. Histologic Type Groups and TNM stage categories were based on the protocol for examination of resection specimens from patients with primary Carcinoma of the colon and rectum by the College of American Pathologists version 4.2.0.0, 2021. Tumor site includes colon: right-sided and left-sided colon, as well as transversal colon. HbA1c, Hemoglobin glycosylated; HDL, high density lipoprotein; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; LDL, low density lipoprotein.